Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Total Non-current Liabilities
All obligations due after more than one year.
Pyxis Oncology, Inc.NASDAQ: PYXS
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 10.0% from a year ago
Total non-current liabilities stood at $16.5M at the end of Q1 FY2026, down 10.0% from a year earlier and down 2.8% from the prior quarter. Over 3 fiscal years it compounded at -3.5% a year.
Context
- Total non-current liabilities amounted to 25.7% of total assets at the end of Q1 FY2026, up 12.2 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -10.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 16.98M USD
- Year-over-year change
- -9.4%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.98M | -9.4% |
| FY2024 | 2024-12-31 | 18.75M | -15.8% |
| FY2023 | 2023-12-31 | 22.26M | +17.7% |
| FY2022 | 2022-12-31 | 18.92M | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's Mar 2026 total non-current liabilities of $16.5M is the 7th highest of the 10 companies compared; the peer median is $28.2M.
- Its year-over-year change of -10.0% is the 5th highest of 9, against a peer median of -11.7%.
- Total non-current liabilities amounts to 25.7% of total assets for PYXS, versus a peer median of 12.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.32B | +88832.8% | -8.4% | 1.5% | |
| Mar 2026 | $234.17M | -6.0% | -10.9% | 105.4% | |
| Mar 2026 | $151.67M | -17.3% | +78.5% | 48.2% | |
| Mar 2026 | $82.75M | -22.3% | +11.9% | 74.8% | |
| Mar 2026 | $28.2M | -30.1% | +2.2% | 12.9% | |
| Mar 2026 | $27.31M | -2.3% | -14.7% | 18.3% | |
| Mar 2026 | $16.5M | -10.0% | -3.5% | 25.7% | |
| Mar 2026 | $12.1M | +16.3% | -10.1% | 9.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding PYXS) | $28.2M | -11.7% | -8.4% | 12.9% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 274.74M | 179.29M | 9.66M | 19.47M | 15.42M |
| Short-term Investments | 0 | 0 | 109.63M | 107.46M | 51.44M |
| Net Receivables | 0 | 598K | 21K | 0 | 700K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.56M | 5.41M | 4.27M | 4.75M | 4.55M |
| Total Current Assets | 278.67M | 186.61M | 124.6M | 132.44M | 72.11M |
| Property, Plant & Equipment (Net) | 1.24M | 24.77M | 24.81M | 22.14M | 19.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 24.31M | 2.6M | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 109K | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 1.35M | 24.77M | 49.12M | 24.74M | 19.42M |
| Total Assets | 280.02M | 211.38M | 173.73M | 157.18M | 91.52M |
| Account Payables | 11.95M | 7.1M | 3.9M | 4.86M | 10.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 7.66M | 0 | 0 |
| Other Current Liabilities | 3.23M | 5.33M | 5.58M | 4.63M | 3.75M |
| Total Current Liabilities | 18.71M | 31.63M | 25.76M | 17.68M | 21.13M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 2.16M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 18.92M | 22.26M | 18.75M | 16.98M |
| Total Liabilities | 18.71M | 50.56M | 48.02M | 36.43M | 38.11M |
| Common Stock | 32K | 34K | 45K | 60K | 63K |
| Retained Earnings | (91.72M) | (212.44M) | (286.23M) | (363.56M) | (443.18M) |
| Accumulated OCI | 0 | 0 | 63K | 170K | 53K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 261.31M | 160.82M | 125.7M | 120.75M | 53.41M |
| Total Debt | 165K | 18.92M | 21.33M | 20.2M | 18.67M |
| Net Debt | (274.57M) | (160.37M) | 11.67M | 727K | 3.25M |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.